Neumora Therapeutics, a brain disease biotech born out of stitching together multiple neuroscience startups, is looking to replicate its original playbook by complementing its seven-drug pipeline with external assets thanks to a September IPO and $520 million balance sheet.
The drugmaker already has its hands full with a
